Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial Agent

Medicinal Research Reviews

Volumn 32, Issue 6, 2012, Pages 1292-1327

  Harris, Frederick ^a   Pierpoint, Lynne ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

5 aminiolevulinic acid; Antibacterial; Antifungal; Antiviral; Photodynamic

Indexed keywords

AMINOLEVULINIC ACID; ANTIINFECTIVE AGENT; PROTOPORPHYRIN;

ACNE VULGARIS; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL DAMAGE; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; DNA DAMAGE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; FUNGAL CONTAMINATION; GENOTYPE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST CELL; IMMUNE RESPONSE; LEISHMANIASIS; LIPOPHILICITY; NEGATIVE FEEDBACK; NONHUMAN; ONYCHOMYCOSIS; OSTEOMYELITIS; PHOTODYNAMIC THERAPY; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS PARTICLE;

AMINOLEVULINIC ACID; ANIMALS; ANTI-INFECTIVE AGENTS; HUMANS; MICROBIAL VIABILITY; PHOTOCHEMOTHERAPY; PRODRUGS; VIRUS INACTIVATION;

EID: 84867464473     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20251     Document Type: Article

References (325)

1. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-A clinical super-challenge. N Engl J Med. 2009;360:439-443.
2. Livermore DM. Has the era of untreatable infections arrived?. J Antimicrob Chemother. 2009;64:i29-i36.
3. Overbye KM, Barrett JF. Antibiotics: Where did we go wrong?. Drug Discov Today. 2005;10:45-52.
4. Projan SJ, Shlaes DM. Antibacterial drug discovery: Is it all downhill from here?. Clin Microbiol Infec. 2004;10:18-22.
5. Sosa AdJ, Byarugaba DK, Amá bile-Cuevas CF, Hsueh P-R, Kariuki S, Okeke In, editors. Antimicrobial resistance in developing countries. New York: Springer; 2009
6. Cars O, Hogberg LD, Murray M, Nordberg O, Sivaraman S, Lundborg CS, So AD, Tomson G. Meeting the challenge of antibiotic resistance. Br Med J. 2008;337:a1438.
7. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med. 2004;10:S70-S76.
8. DiazGranados CA, Cardo DM, McGowan JE. Antimicrobial resistance: International control strategies, with a focus on limited-resource settings. Int J Antimicrob Agents. 2008;32:1-9.
9. Owens RC. Antimicrobial stewardship: Concepts and strategies in the 21st century. Diagn Microbiol Infect Dis. 2008;(1):61:110-128.
10. Alksne LE, Dunman PA. Target-based antimicrobial drug discovery. Method Mol Biol. 2008;431:271-283.
11. Pucci MJ. Use of genomics to select antibacterial targets. Biochem Pharmacol. 2006;71:1066-1072.
12. Pucci MJ. Novel genetic techniques and approaches in the microbial genomics era: Identification and/or validation of targets for the discovery of new antibacterial agents. Drugs R D. 2007;8:201-212.
13. Mills SD. When will the genomics investment pay off for antibacterial discovery?. Biochem Pharmacol. 2006;71:1096-1102.
14. Charifson PS, Grossman TH, Mueller P. The use of structure-guided design to discover new anti-microbial agents: Focus on antibacterial resistance. Anti Infect Agents Med Chem. 2009;8:73-86.
15. Barker JJ. Antibacterial drug discovery and structure-based design. Drug Discov Today. 2006;11:391-404.
16. Schmid MB. Crystallizing new approaches for antimicrobial drug discovery. Biochem Pharmacol. 2006;71:1048-1056.
17. Jagusztyn-Krynicka EK, Wyszynska A. The decline of antibiotic era-New approaches for antibacterial drug discovery. Pol J Microbiol. 2008;57:91-98.
18. Wright GD, Sutherland AD. New strategies for combating multidrug-resistant bacteria. Trends Mol Med. 2007;13:260-267.
19. Coates ARM, Hu YM. Targeting non-multiplying organisms as a way to develop novel antimicrobials. Trends Pharmacol Sci. 2008;29:143-150.
20. Vicente M, Hodgson J, Massidda O, Tonjum T, Henriques-Normark B, Ron EZ. The fallacies of hope: Will we discover new antibiotics to combat pathogenic bacteria in time?. FEMS Microbiol Rev. 2006;30:841-852.
21. Ajesh K, Sreejith K. Peptide antibiotics: An alternative and effective antimicrobial strategy to circumvent fungal infections. Peptides. 2009;30:999-1006.
22. Hirsch T, Jacobsen F, Steinau HU, Steinstraesser L. Host defense peptides and the new line of defence against multiresistant infections. Protein Pept Lett. 2008;15:238-243.
23. Mookherjee N, Hancock REW. Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci. 2007;64:922-933.
24. Escaich S. Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol. 2008;12:400-408.
25. Almeida A, Cunha A, Newton MCM, Alves E, Costa L, Faustino MAF. Phage therapy and photodynamic therapy: Low environmental impact approaches to inactivate microorganisms in fish farming plants. Mar Drugs. 2009;7:268-313.
26. Maisch T. Revitalized strategies against multi-resistant bacteria: Antimicrobial photodynamic therapy and bacteriophage therapy. Anti-Infect Agents Med Chem. 2007;6:145-150.
27. Gorski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, Letkiewicz S, Zimecki M, Filby G. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs. 2009;10:766-774.
28. Brussow H. Phage therapy: The western perspective. In: McGrath S, van Sinderen D, editors. Bacteriophage: genetics and molecular biology. Norwich, UK: Caister Academic Press; 2007.
29. Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci. 2007;6:1234-1245.
30. Zolfaghari PS, Packer S, Singer M, Nair SP, Bennett J, Street C, Wilson M. In vivo killing of Staphylococcus aureus using a light-activated antimicrobial agent. BMC Microbiol. 2009;9:27.
31. Dai TH, Tegos GP, Zhiyentayev T, Mylonakis E, Hamblin MR. Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Laser Surg Med. 2010;42:38-44.
32. Wainwright M, Phoenix DA, Laycock SL, Wareing DRA, Wright PA. Photobactericidal activity of phenothiazinium dyes against methicillin-resistant strains of Staphylococcus aureus. FEMS Microbiol Lett. 1998;160:177-181.
33. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629-641.
34. Maisch T. A new strategy to destroy antibiotic resistant microorganisms: Antimicrobial photodynamic treatment. Mini Rev Med Chem. 2009;9:974-983.
35. Amagasa J. Dye binding and photodynamic action. Photochem Photobiol. 2009;33:947-955.
36. Durantini EN. Photodynamic inactivation of bacteria. Curr Bioact Compd. 2006;2:127-142.
37. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. Photophysics and photochemistry of photodynamic therapy: Fundamental aspects. Lasers Med Sci. 2009;24:259-268.
38. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol. 2008;53:R61-R109.
39. Jori G, Coppellotti O. Inactivation of pathogenic microorganisms by photodynamic techniques: Mechanistic aspects and perspective applications. Anti-Infect Agents Med Chem. 2007;6:119-131.
40. Viola G, Dall'Acqua F. Photosensitization of biomolecules by phenothiazine derivatives. Curr Drug Targets. 2006;7:1135-1154.
41. Jori G, Fabris C, Soncin M, Ferro S, Coppellotti O, Dei D, Fantetti L, Chiti G, Roncucci G. Photodynamic therapy in the treatment of microbial infections: Basic principles and perspective applications. Lasers Surg Med. 2006;38:468-481.
42. Wainwright M. Photoinactivation of viruses. Photochem Photobiol Sci. 2004;3:406-411.
43. Phoenix DA, Harris F. Light activated compounds as antimicrobial agents-Patently obvious?. Recent Pat Antiinfect Drug Discov. 2006;1:181-199.
44. Tardivo JP, Del Giglio A, de Oliveira CS, Gabrielli DS, Junqueira HC, Tada DB, Severino D, de Fátima Turchiello R, Baptista MS. Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications. Photodiagnos Photodynam Ther. 2005;2:175-191.
45. Tuite EM, Kelly JM. Photochemical interactions of methylene-blue and analogs with dna and other biological substrates. J Photochem Photobiol B. 1993;21:103-124.
46. Davies MJ. Reactive species formed on proteins exposed to singlet oxygen. Photochem Photobiol Sci. 2004;3:17-25.
47. Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta. 2005;1703:93-109.
48. Girotti AW. Photosensitized oxidation of membrane lipids: Reaction pathways, cytotoxic effects, and cytoprotective mechanisms. J Photochem Photobiol B. 2001;63:103-113.
49. Girotti AW, Kriska T. Role of lipid hydroperoxides in photo-oxidative stress signaling. Antioxidants Redox Signal. 2004;6:301-310.
50. Goslinski T, Konopka K, Piskorz J, Kryjewski M, Wierzehowski M, Sobiak S. Prospects for photodynamic antimicrobial chemotherapy-PACT. Postepy Mikrobiologii. 2008;47:447-456.
51. Donnelly RF, McCarron PA, Tunney MM. Antifungal photodynamic therapy. Microbiol Res. 2008;163:1-12.
52. Akilov OE, Kosaka S, O'Riordan K, Song XZ, Sherwood M, Flotte TJ, Foley JW, Hasan T. The role of PS molecular charge and structure on the efficacy of photodynamic therapy against Leishmania parasites. Chem Biol. 2006;13:839-847.
53. O'Riordan K, Akilov OE, Hasan T. The potential for photodynamic therapy in the treatment of localized infections. Photodiagn Photodyn Ther. 2005;2:247-262.
54. Hamblin MR, Hasan T. Photodynamic therapy: A new antimicrobial approach to infectious disease?. Photochem Photobiol Sci. 2004;3:436-450.
55. Cassidy CM, Tunney MM, McCarron PA, Donnelly RF. Drug delivery strategies for photodynamic antimicrobial chemotherapy: From benchtop to clinical practice. J Photochem Photobiol B. 2009;95:71-80.
56. Hamblin MR, Brown SB. Photodynamic therapy for infectious disease. Advances in Photodynamic Therapy: Basic, Translational, and Clinical. London, UK: Artech. 2008. p 359-373.
57. Magaraggia M, Jori G. Photodynamic therapy in treatment of infectious diseases: Basic aspects and mechanisms of action. Advances in Photodynamic Therapy: Basic, Translational, and Clinical. London, UK: Artech. 2008. p 337-357.
58. Harris F, Chatfield LK, Phoenix DA. Phenothiazinium based PSs-Photodynamic agents with a multiplicity of cellular targets and clinical applications. Curr Drug Targets. 2005;6:615-627.
59. Allaker RP, Douglas CW. Novel anti-microbial therapies for dental plaque-related diseases. Int J Antimicrob Agents. 2009;33:8-13.
60. Konopka K, Goslinski T. Photodynamic therapy in dentistry. J Dent Res. 2007;86:694-707.
61. Maisch T. Anti-microbial photodynamic therapy: Useful in the future?. Lasers Med Sci. 2007;22:83-91.
62. Calzavara-Pinton PG, Venturini M, Sala R. A comprehensive overview of photodynamic therapy in the treatment of superficial fungal infections of the skin. J Photochem Photobiol B. 2005;78:1-6.
63. Solheim BG. Pathogen reduction of blood components. Transfus Apheresis Sci. 2008;39:75-82.
64. Wainwright M, Mohr H, Walker WH. Phenothiazinium derivatives for pathogen inactivation in blood products. J Photochem Photobiol B. 2007;86:45-58.
65. Parsons C, McCoy CP, Gorman SP, Jones DS, Bell SEJ, Brady C, McGlinchey SM. Anti-infective photodynamic biomaterials for the prevention of intraocular lens-associated infectious endophthalmitis. Biomaterials. 2009;30:597-602.
66. Brady C, Bell SEJ, Parsons C, Gorman SP, Jones DS, McCoy CP. Novel porphyrin-incorporated hydrogels for photoactive intraocular lens biomaterials. J Phys Chem B. 2007;111:527-534.
67. Barcili B. Hydrogels for tissue engineering and delivery of tissue-inducing substances. J Pharm Sci. 2007;96:2197-2223.
68. Funes MD, Caminos DA, Alvarez MG, Fungo F, Otero LA, Durantini EN. Photodynamic properties and photoantimicrobial action of electrochemically generated porphyrin polymeric films. Environ Sci Technol. 2009;43:902-908.
69. Decraene V, Pratten J, Wilson M. Novel light-activated antimicrobial coatings are effective against surface-deposited Staphylococcus aureus. Curr Microbiol. 2008;57:269-273.
70. Wainwright M, Byrne MN, Gattrell MA. Phenothiazinium-based photobactericidal materials. J Photochem Photobiol B. 2006;84:227-230.
71. Wilson M. Light-activated antimicrobial coating for the continuous disinfection of surfaces. Infect Control Hosp Epidemiol. 2003;24:782-784.
72. Carvalho CMB, Tome JPC, Faustino MAF, Neves M, Tome AC, Cavaleiro JAS, Costa L, Alves E, Oliveira A, Cunha A, Almeida A. Antimicrobial photodynamic activity of porphyrin derivatives: Potential application on medical and water disinfection. J Porphyrins Phthalocyanines. 2009;13:574-577.
73. Bonnett R, Krysteva MA, Lalov IG, Artarsky SV. Water disinfection using PSs immobilized on chitosan. Water Res. 2006;40:1269-1275.
74. Fukuda H, Casas A, Batlle A. Aminolevulinic acid: From its unique biological function to its star role in photodynamic therapy. Int J Biochem Cell B. 2005;37:272-276.
75. Dietel W, Pottier R, Pfister W, Schleler P, Zinner K. 5-Aminolaevulinic acid (ALA) induced formation of different fluorescent porphyrins: A study of the biosynthesis of porphyrins by bacteria of the human digestive tract. J Photochem Photobiol B. 2007;86:77-86.
76. Akilov OE, Kosaka S, O'Riordan K, Hasan T. Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. Exp Dermatol. 2007;16:651-660.
77. Fabbrocini G, Di Costanzo MP, Riccardo AM, Quarto M, Colasanti A, Roberti G, Monfrecola G. Photodynamic therapy with topical [delta]-aminolaevulinic acid for the treatment of plantar warts. J Photochem Photobiol B. 2001;61:30-34.
78. Zawislak A, Donnelly RF, McCluggage WG, Price JH, McClelland HR, Woolfson AD, Dobbs S, Maxwell P, McCarron PA. Clinical and immunohistochemical assessment of vulval intraepithelial neoplasia following photodynamic therapy using a novel bioadhesive patch-type system loaded with 5-aminolevulinic acid. Photodiagn Photodyn Ther. 2009;6:28-40.
79. Dai T, Huang Y-Y, Hamblin MR. Photodynamic therapy for localized infections-State of the art. Photodiagn Photodyn Ther. 2009;6:170-188.
80. Luksiene Z, Danilcenko H, Taraseviciene Z, Anusevicius Z, Maroziene A, Nivinskas H. New approach to the fungal decontamination of wheat used for wheat sprouts: Effects of aminolevulinic acid. Int J Food Microbiol. 2007;116:153-158.
81. Ayala F, Grimaldi E, Perfetto B, Donnarumma M, De Filippis A, Donnarumma G, Tufano MA. 5-aminolaevulinic acid and photodynamic therapy reduce HSV-1 replication in HaCat cells through an apoptosis-independent mechanism. Photodermatol Photoimmunol Photomed. 2008;24:237-243.
82. Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta. 2006;1763:723-736.
83. Schobert M, Jahn D. Regulation of heme biosynthesis in non-phototrophic bacteria. J Mol Microbiol Biotechnol. 2002;4:287-294.
84. Heinemann IU, Jahn M, Jahn D. The biochemistry of heme biosynthesis. Arch Biochem Biophys. 2008;474:238-251.
85. O'Brian MR. Heme biosynthesis. In: Schaechter M, editor. Encyclopedia of microbiology. New York: Elsevier; 2009. pp 194-209.
86. Batlle AM. Porphyrins, porphyrias, cancer and photodynamic therapy-A model for carcinogenesis. J Photochem Photobiol B. 1993;20:5-22.
87. Kennedy JC. Outline of the theory and technique of ALA PDT. In: Pottier R, Krammer B, Baumgartner R, Stepp H, editors. Photodynamic therapy with ALA.Cambridge, UK: Royal Society of Chemistry; 2006. pp 1-15.
88. Collaud S, Juzeniene A, Moan J, Lange N. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents. 2004;4:301-316.
89. Schleyer V, Szeimies R-F. ALA/MAL PDT in dermatology. In: Pottier R, Krammer B, Baumgartner R, Stepp H, editors. Photodynamic therapy with ALA. Cambridge, UK: Royal Soceity of Chemistry; 2006. pp 79-127.
90. Nitzan Y, Salmon-Divon M, Shporen E, Malik Z. ALA induced photodynamic effects on gram positive and negative bacteria. Photochem Photobiol Sci. 2004;3:430-435.
91. Rossi R, Bruscino N, Ricceri F, Grazzini M, Dindelli M, Lotti T. Photodynamic treatment for viral infections of the skin. G Ital Dermatol Venereol. 2009;144:79-83.
92. Szeimies R-M. Photodynamic therapy for human papilloma virus-related diseases in dermatology. Med Laser Appl. 2003;18:(2):107-116.
93. Krammer B, Plaetzer K. ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci. 2008;7:283-289.
94. Choudhary S, Nouri K, Elsaie M. Photodynamic therapy in dermatology: A review. Lasers Med Sci. 2009;24:971-980.
95. Klein A, Babilas P, Karrer S, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology-An update 2008. J Der Deutschen Dermatologischen Gesellschaft. 2008;6:839-845.
96. Mitra A, Stables GI. Topical photodynamic therapy for non-cancerous skin conditions. Photodiagn Photodyn Ther. 2006;3:116-127.
97. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J Photochem Photobiol B. 1990;6:143-148.
98. Sibani SA, McCarron PA, Woolfson AD, Donnelly RF. PS delivery for photodynamic therapy. Part 2: Systemic carrier platforms. Expert Opin Drug Deliv. 2008;5:1241-1254.
99. Taylor MN, Gonzalez ML. The practicalities of photodynamic therapy in acne vulgaris. Br J Dermatol. 2009;160:1140-1148.
100. Issa MCA, Manela-Azulay M. Photodynamic therapy: A review of the literature and image documentation. An Bras Dermatol. 2010;85:501-511.
101. Morrow DIJ, Donnelly RF. Novel drug delivery strategies for porphyrins and porphyrin precursors. 2009. Seattle: SPIE-The International Society for Optical Engineering.
102. Morrow DIJ, Garland MJ, McCarron PA, Woolfson AD, Donnelly RF. Innovative drug delivery strategies for topical photodynamic therapy using porphyrin precursors. J Environ Pathol Toxicol Oncol. 2007;26:105-116.
103. Fotinos N, Campo MA, Popowycz F, Gurny R, Lange N. 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. Photochem Photobiol. 2006;82:994-1015.
104. Kloek J, Akkermans W, van Henegouwen G. Derivatives of 5-aminolevulinic acid for photodynamic therapy: Enzymatic conversion into protoporphyrin. Photochem Photobiol. 1998;67:150-154.
105. Fukuda H, Casas A, Batlle A. Use of ALA and ALA derivatives for optimizing ALA-based photodynamic therapy: A review of our experience. J Environ Pathol Toxicol Oncol. 2006;25:127-143.
106. Lopez RF, Lange N, Guy R, Bentley MV. Photodynamic therapy of skin cancer: Controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev. 2004;56:77-94.
107. Giuntini F, Bourre L, MacRobert AJ, Wilson M, Eggleston IM. Improved peptide prodrugs of 5-ALA for PDT: Rationalization of cellular accumulation and protoporphyrin IX production by direct determination of cellular prodrug uptake and prodrug metabolization. J Med Chem. 2009;52:4026-4037.
108. Bourre L, Giuntini F, Eggleston IM, Wilson M, MacRobert AJ. Protoporphyrin IX enhancement by 5-aminolaevulinic acid peptide derivatives and the effect of RNA silencing on intracellular metabolism. Br J Cancer. 2009;100:723-731.
109. Fotinos N, Convert M, Piffaretti JC, Gurny R, Lange N. Effects on gram-negative and gram-positive bacteria mediated by 5-aminolevulinic acid and 5-aminolevulinic acid derivatives. Antimicrob Agents Chemother. 2008;52:1366-1373.
110. Vallinayagam R, Schmitt F, Barge J, Wagnieres G, Wenger V, Neier R, Juillerat-Jeanneret L. Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer. Bioconjug Chem. 2008;19:821-839.
111. Gerritsen MJP, Smits T, Kleinpenning MM, van de Kerkhof PCM, van Erp PEJ. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology. 2009;218:193-202.
112. Juzeniene A, Juzenas P, Kaalhus O, Iani V, Moan J. Temperature effect on accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin. Photochem Photobiol. 2002;76:452-456.
113. Ramstad S, Le Anh-Vu N, Johnsson A. The temperature dependence of porphyrin production in Propionibacterium acnes after incubation with 5-aminolevulinic acid (ALA) and its methyl ester (m-ALA). Photochem Photobiol Sci. 2006;5:66-72.
114. Yang JB, Chen ACH, Wu QH, Jiang S, Liu XM, Xiong LY, Xia YM. The influence of temperature on 5-aminolevulinic acid-based photodynamic reaction in keratinocytes in vitro. Photodermatol Photoimmunol Photomed. 2010;26:83-88.
115. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem Photobiol. 2005;81:750-767.
116. de Leeuw J, van der Beek N, Bjerring P, Neumann HAM. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in combination with topical keratolytic agents. J Eur Acad Dermatol Venereol 24:460-469.
117. de Campos Araújo LMP, Thomazine JA, Lopez RFV. Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm. 2010;75:48-55.
118. Winkler A, Müller-Goymann CC. The influence of topical formulations on the permeation of 5-aminolevulinic acid and its n-butyl ester through excised human stratum corneum. Eur J Pharm Biopharm. 2005;60:427-437.
119. Donnelly RF, Morrow DIJ, McCarron PA, Woolfson AD, Morrissey A, Juzenas P, Juzeniene A, Iani V, McCarthy HO, Moan J. Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: Potential for enhanced topical photodynamic therapy. J Control Release. 2008;129:154-162.
120. Donnelly RF, Singh TRR, Tunney MM, Morrow DIJ, McCarron PA, O'Mahony C, Woolfson AD. Microneedle arrays allow lower microbial penetration than hypodermic needles in vitro. Pharm Res. 2009;26:2513-2522.
121. Ericson MB, Wennberg AM, Larko O. Review of photodynamic therapy in actinic keratosis and basal cell carcinoma. Ther Clin Risk Manag. 2008;4:1-9.
122. Serra A, Pineiro M, Pereira N, Rocha Gonsalves A, Laranjo M, Abrantes M, Botelho F. A look at clinical applications and developments of photodynamic therapy. Oncol Rev. 2008;2:235-249.
123. Morrow DIJ, McCarron PA, Woolfson AD, Juzenas P, Juzeniene A, Iani V, Moan J, Donnelly RF. Novel patch-based systems for the localised delivery of ALA-esters. J Photochem Photobiol B. 2010;101:59-69.
124. Verkamp E, Backman VM, Bjornsson JM, Soll D, Eggertsson G. The periplasmic dipeptide permease system transports 5-aminolevulinic acid in Escherichia coli. J Bacteriol. 1993;175:1452-1456.
125. Elliott T. Transport of 5-aminolevulinic acid by the dipeptide permease in Salmonella typhimurium. J Bacteriol. 1993;175:325-331.
126. Daniel H, Spanier B, Kottra G, Weitz D. From bacteria to man: Archaic proton-dependent peptide transporters at work. Physiology. 2006;21:93-102.
127. King ND, Obrian MR. Identification of the lrp gene in Bradyrhizobium japonicum and its role in regulation of delta-aminolevulinic acid uptake. J Bacteriol. 1997;179:1828-1831.
128. Grinholc M, Szramka B, Olender K, Graczyk A. Bactericidal effect of photodynamic therapy against methicillin-resistant Staphylococcus aureus strain with the use of various porphyrin PSs. Acta Biochimica Pol. 2007;54:665-670.
129. Gootz TD, Marra A. Acinetobacter baumannii: An emerging multidrug-resistant threat. Exp Rev Anti Infect Ther. 2008;6:(3):309-325.
130. Luksiene Z, Zukauskas A. Prospects of photosensitization in control of pathogenic and harmful micro-organisms. J Appl Microbiol. 2009;107:1415-1424.
131. Nitzan Y, Kauffman M. Endogenous porphyrin production in bacteria by delta-aminolaevulinic acid and subsequent bacterial photoeradication. Lasers Med Sci. 1999;14:269-277.
132. Bruce-Micah R, Gamm U, Huttenberger D, Cullum J, Foth HJ. Photodynamic inactivation of the models. Mycobacterium phlei and Mycobacterium smegmatis in vitro. In: Ronald S, Lothar DL, editors. Therapeutic Laser Applications and Laser-Tissue Interactions IV. SPIE; 2009. pp 73731L-73731L-7.
133. Ramstad S, Futsaether CM, Johnsson A. Porphyrin sensitization and intracellular calcium changes in the prokaryote Propionibacterium acnes. J Photochem Photobiol B. 1997;40:141-148.
134. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67:593-656.
135. van der Meulen FW, Ibrahim K, Sterenborg HJ, Alphen LV, Maikoe A, Dankert J. Photodynamic destruction of Hemeophilus parainfluenzae by endogenously produced porphyrins. J Photochem Photobiol B. 1997;40:204-208.
136. Gabor F, Szocs K, Maillard P, Csik G. Photobiological activity of exogenous and endogenous porphyrin derivatives in Escherichia coli and Enterococcus hirae cells. Radiat Environ Biophys. 2001;40:145-151.
137. Bisland SK, Dadani FN, Chien C, Wilson BC. Hyperbaric oxygen therapy augments the photodynamic action of methylene blue against bacteria in vitro-art. no. 64270F. Optical methods for tumor treatment and detection: Mechanisms and techniques in photodynamic therapy XVI, Proceedings of SPIE, vol. 6427, 2007. F4270-F4270.
138. Sailer R, Strauss WSL, Konig K, Ruck A, Steiner R. Correlation between porphyrin biosynthesis and photodynamic inactivation of Pseudomonas aeruginosa after incubation with 5 aminolaevulinic acid. J Photochem Photobiol B. 1997;39:236-242.
139. Lee CF, Lee CJ, Chen CT, Huang CT. delta-Aminolaevulinic acid mediated photodynamic antimicrobial chemotherapy on Pseudomonas aeruginosa planktonic and biofilm cultures. J Photochem Photobiol B. 2004;75:21-25.
140. Bisland SK, Chien C, Wilson BC, Burch S. Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Photochem Photobiol Sci. 2006;5:31-38.
141. Bisland SK, Chien C, Wilson BC, Burch S. Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Opt Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIV. 2005;5689:26-38.
142. Karrer S, Szeimies RM, Ernst S, Abels C, Baumler W, Landthaler M. Photodynamic inactivation of staphylococci with 5-aminolaevulinic acid or photofrin. Lasers Med Sci. 1999;14:54-61.
143. Olejek A, Kozak-Darmas I, Kellas-Sleczka S, Steplewska K, Biniszkiewicz T, Birkner B, Jarek A, Nowak L, Stencel-Gabriel K, Sieron A. Effectiveness of photodynamic therapy in the treatment of Lichen sclerosus: Cell changes in immunohistochemistry. Neuroendocrinol Lett. 2009;30:547-551.
144. Sotiriou E, Panagiotidou D, Ioannidis D. An open trial of 5-aminolevulinic acid photodynamic therapy for vulvar lichen sclerosus. Eur J Obstet Gynaecol Reprod Biol. 2008;141:187-188.
145. Zawislak AA, McCluggage WG, Donnelly RF, Maxwell P, Price JH, Dobbs SP, McClelland HR, Woolfson AD, McCarron PA. Response of vulval lichen sclerosus and squamous hyperplasia to photodynamic treatment using sustained topical delivery of aminolevulinic acid from a novel bioadhesive patch system. Photodermatol Photoimmunol Photomed. 2009;25:111-113.
146. Eisendle K, Zelger B. The expanding spectrum of cutaneous borreliosis. G Ital Dermatol Venereol. 2009;144:157-171.
147. Horn M, Wolf P. Topical methyl aminolevulinate photodynamic therapy for the treatment of folliculitis. Photodermatol Photoimmunol Photomed. 2007;23:145-147.
148. Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis. 2008;21:122-128.
149. Katsambas A, Dessinioti C. New and emerging treatments in dermatology: Acne. Dermatol Ther. 2008;21:86-95.
150. Nestor MS. The use of photodynamic therapy for treatment of acne vulgaris. Dermatol Clin. 2007;25:47-57.
151. Lomholt HB, Kilian M. [Is acne caused by colonization with the "wrong" strain of Propionibacterium acnes? A review of the role of Propionibacterium acnes in acne]. Ugeskr Laeger. 2008;170:1234-1237.
152. Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol. 2001;144:575-579.
153. Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy for acne vulgaris with topical 5-aminolevulinic acid. Arch Dermatol. 2000;136:1093-1095.
154. Hongcharu W, Taylor CR, Chang YC, Aghassi D, Suthamjariya K, Anderson RR. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Investig Dermatol. 2000;115:183-192.
155. Ramberg K, Melo TB, Johnsson A. In situ assessment of porphyrin PSs in Propionibacterium acnes. Z Naturforsch C. 2004;59:93-98.
156. Ashkenazi H, Malik Z, Harth Y, Nitzan Y. Eradication of Propionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light. FEMS Immunol Med Microbiol. 2003;35:17-24.
157. Fotinos N, Mikulic J, Convert M, Campo MA, Piffaretti JC, Gurny R, Lange N. 5-ALA derivative-mediated photoinactivation of Propionibacterium acnes. J Dermatol Sci. 2009;56:212-214.
158. Divaris DXG, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair-follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin-ix fluorescence. Am J Pathol. 1990;136:891-897.
159. Sakamoto FH, Tannous Z, Doukas AG, Farinelli WA, Smith NA, Zurakowski D, Anderson RR. Porphyrin distribution after topical aminolevulinic acid in a novel porcine model of sebaceous skin. Lasers Surg Med. 2009;41:154-160.
160. Kosaka S, Kawana S, Zouboulis CC, Hasan T, Ortel B. Targeting of sebocytes by aminolevulinic acid-dependent photosensitization. Photochem Photobiol. 2006;82:453-457.
161. Pollock B, Turner D, Stringer MR, Bojar RA, Goulden V, Stables GI, Cunliffe WJ. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: A study of clinical efficacy and mechanism of action. Br J Dermatol. 2004;151:616-622.
162. Bryld LE, Jemec GBE. The bacterial flora of the skin surface following routine MAL-PDT. J Dermatol Treat. 2006;17:222-223.
163. Warren CB, Karai LJ, Vidimos A, Maytin EV. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J Am Acad Dermatol. 2009;61:1033-1043.
164. Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: A critical review from basics to clinical practice Part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol. 2010;63:195-211.
165. Taub AF. Procedural treatments for acne vulgaris. Dermatol Surg. 2007;33:1005-1026.
166. Richey DF. Aminolevulinic acid photodynamic therapy for sebaceous gland hyperplasia. Dermatol Clin. 2007;25:59-65.
167. MacCormack MA. Photodynamic therapy in dermatology: An update on applications and outcomes. Semin Cutan Med Surg. 2008;27:52-62.
168. Proenca-Modena JL, Acrani GO, Brocchi M. Helicobacter pylori: Phenotypes, genotypes and virulence genes. Future Microbiol. 2009;4:223-240.
169. Hamblin MR, Viveiros J, Yang CM, Ahmadi A, Ganz RA, Tolkoff MJ. Helicobacter pylori accumulates photoactive porphyrins and is killed by visible light. Antimicrob Agents Chemother. 2005;49:2822-2827.
170. Wilder-Smith CH, Wilder-Smith P, Grosjean P, van den Bergh H, Woodtli A, Monnier P, Dorta G, Meister F, Wagnieres G. Photoeradication of Helicobacter pylori using 5-aminolevulinic acid: Preliminary human studies. Lasers Surg Med. 2002;31:18-22.
171. Hammer-Wilson MJ, Gray RM, Wilder-Smith P, Meister F, Osann K, Wilder-Smith CH. Fluorescence diagnostics of Helicobacter pylori-infected human gastric mucosa: Establishing technique and validity. Scand J Gastroenterol. 2007;42:941-950.
172. Bryld LE, Jemec GBE. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol. 2007;21:1199-1202.
173. Katz B, Patel V. Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. J Drugs Dermatol. 2006;5:6-8.
174. Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatologic diseases. Eur J Dermatol. 2009;19:431-444.
175. Szlachcic A. The link between Helicobacter pylori infection and rosacea. J Eur Acad Dermatol Venereol. 2002;16:328-333.
176. Wiegell SR, Kongshoj B, Wulf HC. Mycobacterium marinum infection cured by photodynamic therapy. Arch Dermatol. 2006;142:1241-1242.
177. Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Exp Opin Pharmacother. 2007;8:2965-2978.
178. Petrini B. Mycobacterium marinum: Ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis. 2006;25:609-613.
179. Cosma CL, Sherman DR, Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol. 2003;57:641-676.
180. Chim N, McMath LM, Beeby M, Goulding CW. Advances in Mycobacterium tuberculosis structural genomics: Investigating potential chinks in the armor of a deadly pathogen. Infect Disord Drug Targets. 2009;9:475-492.
181. Bruce-Micah R, Hüttenberger D, Freitag L, Cullum J, Foth HJ. Pharmacokinetic of ALA and h-ALA induced Porphyrins in the models Mycobacterium phlei and Mycobacterium smegmatis. J Photochem Photobiol B. 2009;97:1-7.
182. Tyagi JS, Sharma D. Mycobacterium smegmatis and tuberculosis. Trends Microbiol. 2002;10:68-69.
183. Ramakrishnan L. Using Mycobacterium marinum and its hosts to study tuberculosis. Curr Sci. 2004;86:82-92.
184. Branca AA, Baglioni C. Evidence that type-i and type-ii interferons have different receptors. Nature. 1981;294:768-770.
185. Gordon SV, Bottai D, Simeone R, Stinear TP, Brosch R. Pathogenicity in the tubercle bacillus: molecular and evolutionary determinants. Bioessays. 2009;31:378-388.
186. Schleier P, Berndt A, Zinner K, Zenk W, Dietel W, Pfister W. ALA-based fluorescence diagnosis of malignant oral lesions in the presence of bacterial porphyrin formation-art. no. 613908. Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XV, Proceedings of SPIE, vol. 6139; 2006. p 46-53.
187. Hamad LO, Vervoorts A, Hennig T, Bayer R. Ex vivo photodynamic diagnosis to detect malignant cells in oral brush biopsies. Lasers Med Sci. 2009;25:293-301.
188. Warriner K, Namvar A. What is the hysteria with Listeria? Trends Food Sci Technol. 2009;20:245-254.
189. Castillo ADC, Martinez LHP, Apodaca NLC. Salmonellosis and campylobacteriosis, the most prevalent zoonosis in the world. Vet Mex. 2008;39:81-90.
190. Buchovec I, Vaitonis Z, Luksiene Z. Novel approach to control Salmonella enterica by modern biophotonic technology: Photosensitization. J Appl Microbiol. 2009;106:748-754.
191. Buchovec I, Paskeviciute E, Luksiene Z. Photosensitization-based inactivation of food pathogen Listeria monocytogenes in vitro and on the surface of packaging material. J Photochem Photobiol B. 2010;99:9-14.
192. Stenfors Arnesen LP, Fagerlund A, Granum PE. From soil to gut: Bacillus cereus and its food poisoning toxins. FEMS Microbiol Rev. 2008;32:579-606.
193. Luksiene Z, Buchovec I, Paskeviciute E. Inactivation of food pathogen Bacillus cereus by photosensitization in vitro and on the surface of packaging material. J Appl Microbiol. 2009;107:2037-2046.
194. Marc YL, Buchovec I, George SM, Baranyi J, Luksiene Z. Modelling the photosensitization-based inactivation of Bacillus cereus. J Appl Microbiol. 2009;107:1006-1011.
195. Lemon KP, Earl AM, Vlamakis HC, Aguilar C, Kolter R. Biofilm development with an emphasis on Bacillus subtilis. Bacterial Biofilms. 2008;322:1-16.
196. Brooks JD, Flint SH. Biofilms in the food industry: Problems and potential solutions. Int J Food Sci Technol. 2008;43:2163-2176.
197. Gandhi M, Chikindas ML. Listeria: A foodborne pathogen that knows how to survive. Int J Food Microbiol. 2007;113:(1):1-15.
198. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol. 2009;11:1034-1043.
199. Fitzpatrick F, Humphreys H, O'Gara JP. The genetics of staphylococcal biofilm formation-will a greater understanding of pathogenesis lead to better management of device-related infection?. Clin Microbiol Infect. 2005;11:967-973.
200. Rohde H, Mack D, Christner M, Burdelski C, Franke G, Knobloch JKM. Pathogenesis of staphylococcal device-related infections: From basic science to new diagnostic, therapeutic and prophylactic approaches. Rev Med Microbiol. 2006;17:45-54.
201. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol. 2008;52:13-22.
202. McCann MT, Gilmore BF, Gorman SP. Staphylococcus epidermidis device-related infections: Pathogenesis and clinical management. J Pharm Pharmacol. 2008;60:1551-1571.
203. Brady RA, Calhoun JH, Leid JG, Shirtliff ME. Infections of orthopaedic implants and devices. Springer Series on Biofilms: 3. Berlin: Springer-Verlag; 2009. pp 15-55.
204. Smetana Z, Malik Z, Orenstein A, Mendelson E, BenHur E. Treatment of viral infections with 5-aminolevulinic acid and light. Lasers Surg Med. 1997;21:351-358.
205. Tao J-n, Duan S-m, Li J. [Experimental studies on treatment of HSV infections with photodynamic therapy using 5-aminolevulinic acid]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007;21:79-82.
206. Kvacheva ZB, Lobanok YS, Votyakov VI, Shukanova NA, Vorobey AV, Nikolayeva SN, Titov LP. Photodynamic inhibition of infection caused by herpes simplex virus type 1 in the cultured cells, by using 5-aminolevulinic acid-induced porphyrins. Vopr Virusol. 2005;50:44-47.
207. Herget GW, Riede UN, Schmitt-Graff A, Lubbert M, Neumann-Haefelin D, Kohler G. Generalized herpes simplex virus infection in an immunocompromised patient-Report of a case and review of the literature. Pathol Res Pract. 2005;201:123-129.
208. Donnelly RF, McCarron PA, Ma LW, Juzenas P, Iani V, Woolfson AD, Zawislak AA, Moan J. Facilitated delivery of ALA to inaccessible regions via bioadhesive patch systems. J Environ Pathol Toxicol Oncol. 2006;25:389-402.
209. Buggiani G, Troiano M, Rossi R, Lotti T. Photodynamic therapy: Off-label and alternative use in dermatological practice. Photodiagn Photodyna Ther. 2008;5:134-138.
210. Orth G, Mahy BWJ, van Regenmortel MHV. Papillomaviruses: general features of human viruses. Encyclopedia of virology. Oxford: Academic Press; 2008. pp 8-18.
211. Ammann R, Hunziker T, Braathen LR. Topical photodynamic therapy in verrucae-A pilot-study. Dermatology. 1995;191:346-347.
212. Schroeter CA, Kaas L, Waterval JJ, Bos PM, Neumann HAM. Successful treatment of periungual warts using photodynamic therapy: A pilot study. J Eur Acad Dermatol Venereol. 2007;21:1170-1174.
213. Liang J, Lu XN, Tang H, Zhang Z, Fan J, Xu JH. Evaluation of photodynamic therapy using topical aminolevulinic acid hydrochloride in the treatment of Condylomata acuminata: A comparative, randomized clinical trial. Photodermatol Photoimmunol Photomed. 2009;25:293-297.
214. Soergel P, Loning M, Staboulidou I, Schippert C, Hillemanns P. Photodynamic diagnosis and therapy in gynecology. J Environ Path Toxicol Oncol. 2008;27:307-320.
215. Ekonjo GB, Saleh Y, Kasiak J, Gryboś M, Teterycz E, Korzeniewski J, Siewiński M, Da ogonek browski A, Małgorzata S. In vivo application of 5-aminolevulinic acid in the treatment of papillomavirus infection in women with cervical lesions after detection and genotyping using PCR techniqueI. Internet J Gynecol Obstet. 2006;6:
216. Wierrani F, Kubin A, Jindra R, Henry M, Gharehbaghi K, Grin W, Soltz-Szotz J, Alth G, Grunberger W. 5-aminolevulinic acid-mediated photodynamic therapy of intraepithelial neoplasia and human papillomavirus of the uterine cervix-A new experimental approach. Cancer Detect Prev. 1999;23:351-355.
217. Yamaguchi S, Tsuda H, Takemori M, Nakata S, Nishimura S, Kawamura N, Hanioka K, Inoue T, Nishimura R. Photodynamic therapy for cervical intraepithelial neoplasia. Oncology. 2005;69:110-116.
218. Hillemanns P, Wang XL, Staehle S, Michels W, Dannecker C. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO2 laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol. 2006;100:271-275.
219. Soergel P, Wang X, Stepp H, Hertel H, Hillemanns P. Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate. Lasers Surg Med. 2008;40:611-615.
220. Winters U, Daayana S, Lear JT, Tomlinson AE, Elkord E, Stern PL, Kitchener HC. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res. 2008;14:5292-5299.
221. Keefe KA, Tadir Y, Tromberg B, Berns M, Osann K, Hashad R, Monk BJ. Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid. Lasers Surg Med. 2002;31:289-293.
222. McCarron PA, Donnelly RF, Woolfson AD. Autoradiographic and scintillation analysis of 5-aminolevulinic acid permeation through epithelialised tissue: Implications for topical photodynamic therapy of superficial gynaecological neoplasias. Pharm Res. 2008;25:812-826.
223. Gormley RH, Kovarik CL. Dermatologic manifestations of HPV in HIV-infected individuals. Curr HIV/AIDS Rep. 2009;6:130-138.
224. Mudrikova T, Jaspers C, Ellerbroek R, Hoepelman A. HPV related anogenitaldisease and HIV infection: Not always "ordinary" Condylomata acuminata. Neth J Med. 2008;66:98-102.
225. Berk DR, Bruckner AL, Lu D. Epidermodysplasia verruciform-like lesions in an HIV patient. Dermatol Online J. 2009;15:1.
226. Rogers HD, Macgregor JL, Nord KM, Tyring S, Rady P, Engler DE, Grossman ME. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol. 2009;60:315-320.
227. Karrer S, Szeimies RM, Abels C, Wlotzke U, Stolz W, Landthaler M. Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol.140:935-938.
228. Orth G. Host defenses against human papillomaviruses: Lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol. 2008;321:59-83.
229. Chaudhary M, Kulkarni M. Molluscum contagiosum in human immunodeficiency virus infected patients. Indian J Dent Res. 2008;19:155-159.
230. Gold MH, Moiin A. Treatment of verrucae vulgaris and molluscum contagiosum with photodynamic therapy. Dermatol Clin. 2007;2:75-80.
231. Gold MH, Boring MM, Bridges TM, Bradshaw VL. The successful use of ALA-PDT in the treatment of recalcitrant molluscum contagiosum. J Drugs Dermatol. 2004;3:187-190.
232. Hillemanns P, Wang X, Hertel H, Andikyan V, Hillemanns M, Stepp H, Soergel P. Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2008;198:300.e301-e307.
233. Wang HW, Wang XL, Zhang LL, Guo MX, Huang Z. Aminolevulinic acid (ALA)-assisted photodynamic diagnosis of subclinical and latent HPV infection of external genital region. Photodiagn Photodyn Ther. 2008;5:251-255.
234. Wang XL, Wang HW, Huang Z, Stepp H, Baumgartner R, Dannecker C, Hillemanns P. Study of protoporphyrin IX (PpIX) pharmacokinetics after topical application of 5-aminolevulinic acid in urethral condylomata acurninata. Photochem Photobiol. 2007;83:1069-1073.
235. Andrejevic-Blant S, Major A, Ludicke F, Ballini JP, Wagnieres G, van den Bergh H, Pelte MF. Time-dependent hexaminolaevulinate induced protoporphyrin IX distribution after topical application in patients with cervical intraepithelial neoplasia: A fluorescence microscopy study. Lasers Surg Med. 2004;35:276-283.
236. Fritsch C, Ruzicka T. Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. J Environ Pathol Toxicol Oncol. 2006;25:425-439.
237. Wang HW, Wang XL, Zhang LL, Guo MX, Huang Z. Aminolevulinic acid (ALA)-assisted photodynamic diagnosis of subclinical and latent HPV infection of external genital region. Photodiagnos Photodynam Ther. 2008;5:251-255.
238. Smucler R, Jatsova E. Comparative study of aminolevulic acid photodynamic therapy plus pulsed dye laser versus pulsed dye laser alone in treatment of viral warts. Photomed Laser Surg. 2005;23:202-205.
239. Chow LT, Broker TR. Mechanisms and regulation of papillomavirus DNA replication.In: Campo MS, editor. Papillomavirus research: From natural history to vaccines and beyond. Norwich, UK: Caister Academic Press; 2006. pp 193-206.
240. Stender IM, Borgbjerg FM, Villumsen J, Lock-Andersen J, Wulf HC. Pain induced by photodynamic therapy of warts. Photodermatol Photoimmunol Photomed. 2006;22:304-309.
241. Moiin A. Photodynamic therapy for molluscum contagiosum infection in HIV-coinfected patients: Review of 6 patients. J Drugs Dermatol. 2003;2:637-639.
242. Mullard A. Malaria-Picking Plasmodium falciparum apart. Nat Rev Microbiol. 2008;6:95-95.
243. Walther B, Walther M. What does it take to control malaria? Ann Trop Med Parasitol. 2007;101:657-672.
244. Sato S, Clough B, Coates L, Wilson RJM. Enzymes for heme biosynthesis are found in both the mitochondrion and plastid of the malaria parasite Plasmodium falciparum. Protist. 2004;155:117-125.
245. Padmanaban G, Nagaraj VA, Rangarajan PN. An alternative model for heme biosynthesis in the malarial parasite. Trends Biochem Sci. 2007;32:443-449.
246. Nagaraj VA, Arumugam R, Gopalakrishnan B, Jyothsna YS, Rangarajan PN, Padmanaban G. Unique properties of Plasmodium falciparum porphobilinogen deaminase. J Biol Chem. 2008;283:437-444.
247. Smith TG, Kain KC. Inactivation of Plasmodium falciparum by photodynamic excitation of heme-cycle intermediates derived from delta-aminolevulinic acid. J Infect Dis. 2004;190:184-191.
248. van der Snoek EM, Robinson DJ, van Hellemond JJ, Neumann HAM. A review of photodynamic therapy in cutaneous leishmaniasis. J Eur Acad Dermatol Venereol. 2008;22:918-922.
249. Palumbo E. Current treatment for cutaneous leishmaniasis: A review. Am J Ther. 2009;16:178-182.
250. Sohl S, Kauer F, Paasch U, Simon JC. Photodynamic treatment of cutaneous leishmaniasis. J Dtsch Dermatol Ges. 2007;5:128-130.
251. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: A placebo-controlled, randomized clinical trial. Clin Exp Dermatol. 2006;31:634-637.
252. Enk CD, Fritsch C, Jonas F, Nasereddin A, Ingber A, Jaffe CL, Ruzicka T. Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol. 2003;139:432-434.
253. Ghaffarifar F, Jorjani O, Mirshams M, Miranbaygi MH, Hosseini ZK. Photodynamic therapy as a new treatment of cutaneous leishmaniasis. East Mediterr Health J. 2006;12:902-908.
254. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC, Lennard NJ, Caler E, Hamlin NE, Haas B, Bohme U, Hannick L, Aslett MA, Shallom J, Marcello L, Hou L, Wickstead B, Alsmark UC, Arrowsmith C, Atkin RJ, Barron AJ, Bringaud F, Brooks K, Carrington M, Cherevach I, Chillingworth TJ, Churcher C, Clark LN, Corton CH, Cronin A, Davies RM, Doggett J, Djikeng A, Feldblyum T, Field MC, Fraser A, Goodhead I, Hance Z, Harper D, Harris BR, Hauser H, Hostetler J, Ivens A, Jagels K, Johnson D, Johnson J, Jones K, Kerhornou AX, Koo H, Larke N, Landfear S, Larkin C, Leech V, Line A, Lord A, Macleod A, Mooney PJ, Moule S, Martin DM, Morgan GW, Mungall K, Norbertczak H, Ormond D, Pai G, Peacock CS, Peterson J, Quail MA, Rabbinowitsch E, Rajandream MA, Reitter C, Salzberg SL, Sanders M, Schobel S, Sharp S, Simmonds M, Simpson AJ, Tallon L, Turner CM, Tait A, Tivey AR, Van Aken S, Walker D, Wanless D, Wang S, White B, White O, Whitehead S, Woodward J, Wortman J, Adams MD, Embley TM, Gull K, Ullu E, Barry JD, Fairlamb AH, Opperdoes F, Barrell BG, Donelson JE, Hall N, Fraser CM, Melville SE, El-Sayed NM. The genome of the African trypanosome Trypanosoma brucei. Science. 2005;309:416-422.
255. Sah JF, Ito H, Kolli BK, Peterson DA, Sassa S, Chang KP. Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J Biol Chem. 2002;277:14902-14909.
256. Kosaka S, Akilov OE, O'Riordan K, Hasan T. A mechanistic study of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. J Investig Dermatol Symp Proc. 2007;127:1546-1549.
257. de Bruijn HS, Sluiter W, van der Ploeg-van den Heuvel A, Sterenborg HJ, Robinson DJ. Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy. Photodermatol Photoimmunol Photomed. 2006;22:238-246.
258. Stafford JL, Neumann NF, Belosevic M. Macrophage-mediated innate host defense against protozoan parasites. Crit Rev Microbiol. 2002;28:(3):187-248.
259. Bermundez-Mortetti M, Correa-Garcia S, Ramos E, Battle A. Delta-aminolevulinic acid uptake is mediated by the gamma-aminobutyric acid-specific permease UGA4. Cell Mol Biol (Noisy-Le-Grand). 1996;42:519-523.
260. Moretti B, Correa S, Battle A. Porphyrin biosynthesis intermediates are not regulating delta-aminolevulinic acid transport in Saccaromyces cerevisiae. Biochem Biophys Res Comm. 2000;272:946-950.
261. Bermudez Moretti M, Perullini AM, Batlle A, Correa Garcia S. Expression of the UGA4 gene encoding the delta-aminolevulinic and gamma-aminobutyric acids permease in Saccharomyces cerevisiae is controlled by amino acid-sensing systems. Arch Microbiol. 2005;184:137-140.
262. Bermudez Moretti M, Correa Garcia S, Batlle A. Porphyrin biosynthesis intermediates are not regulating delta-aminolevulinic acid transport in Saccharomyces cerevisiae. Biochem Biophys Res Commun. 2000;272:946-950.
263. Moretti MB, Batlle A, Garcia SC. UGA4 gene encoding the gamma-aminobutyric acid permease in Saccharomyces cerevisiae is an acid-expressed gene. Int J Biochem Cell Biol. 2001;33:1202-1207.
264. Strakhovskaya MG, Shumarina AO, Fraikin GY, Rubin AB. Endogenous porphyrin accumulation and photosensitization in the yeast Saccharomyces cerevisiae in the presence of 2, 2′-dipyridyl. J Photochem Photobiol B. 1999;49:18-22.
265. Strakhovskaya MG, Shumarina AO, Fraikin GY, Rubin AB. Synthesis of protoporphyin IX induced by 5-aminolevulinic acid in yeast cells in the presence of 2, 2-dipyridyl. Biochem Moscow. 1998;63:859-863.
266. Shumarina AO, Strakhovskaia MG, Turovetskii VB, Fraikin G. Photodynamic damage of yeast subcellular fraction induced by elevated levels of endogenous protoporphyrin IX]. Mikrobiologiia. 2003;72:488-492.
267. Lee JW, Kim BJ, Kim MN. Photodynamic therapy: new treatment for recalcitrant malassezia folliculitis. Lasers Surg Med. 2010;42:192-196.
268. Kim YJ, Kim YC. Successful treatment of pityriasis versicolor with 5-aminolevulinic acid photodynamic therapy. Arch Dermatol. 2007;143:1218-1220.
269. Crespo-Erchiga V, Florencio VD. Malassezia yeasts and pityriasis versicollor. Curr Opin Infect Dis. 2006;19:139-147.
270. Monfrecola G, Procaccini EM, Bevilacqua A, Manco A, Calabro G, Santoianni P. In vitro effect of 5-aminolaevulinic acid plus visible light on Candida albicans. Photochem Photobiol Sci. 2004;3:419-422.
271. Oriel S, Nitzan Y. Photoinactivation of Candida albicans by its own endogenous porphyrins. Curr Microbiol. 2010;60:117-123.
272. Egusa H, Soysa NS, Ellepola AN, Yatani H, Samaranayake LP. Oral candidosis in HIV-infected patients. Curr HIV Res. 2008;(6):6:485-499.
273. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51:2-15.
274. Smijs TGM, Pavel S. The susceptibility of dermatophytes to photodynamic treatment with special focus on Trichophyton rubrum. Photochem Photobiol. 2011;87:2-13.
275. Kamp H, Tietz HJ, Lutz M, Piazena H, Sowyrda P, Lademann J, Blume-Peytavi U. Antifungal effect of 5-aminolevulinic acid PDT in Trichophyton rubrum. Mycoses. 2005;48:101-107.
276. Sotiriou E, Panagiotidou D, Ioannides D. 5-aminolevulininic acid photodynamic therapy treatment for tinea cruris caused by Trichophyton rubrum: Report of 10 cases. J Eur Acad Dermatol Venereol. 2009;23:341-342.
277. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin. 2003;21:395-400.
278. Mendoza N, Arora A, Arias CA, Hernandez CA, Madkam V, Tyring SK, Elias JA, Michael RM, Michael AP. Cutaneous and subcutaneous mycoses. Clinical mycology (Second edition). Edinburgh: Churchill Livingstone; 2009. pp 509-523.
279. Sotiriou E, Koussidou-Ermonti T, Chaidemenos G, Apalla Z, Ioannides D. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial. Acta Derm Venereol. 2010;90:(2):216-217.
280. McCarthy DJ. Origins of onychomycosis. Clin Podiatr Med Surg. 2004;21533-21553.
281. Watanabe D, Kawamura C, Masuda Y, Akita Y, Tamada Y, Matsumoto Y. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol. 2008;144:19-21.
282. Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol. 2008;59:S75-S76.
283. Donnelly RF, McCarron PA, Lightowler JM, Woolfson AD. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J Control Release. 2005;103:381-392.
284. Calzavara-Pinton PG, Venturini M, Capezzera R, Sala R, Zane C. Photodynamic therapy of interdigital mycoses of the feet with topical application of 5-aminolevulinic acid. Photodermatol Photoimmunol Photomed. 2004;20:144-147.
285. Sotiriou E, Koussidou T, Patsatsi A, Apalla Z, Ioannides D. 5-Aminolevulinic acid-photodynamic treatment for dermatophytic tinea pedis of interdigital type: A small clinical study. J Eur Acad Dermatol Venereol. 2009;23:203-204.
286. Qiao J, Li R, Ding Y, Fang H. Photodynamic therapy in the treatment of superficial mycoses: An evidence-based evaluation. Mycopathologia. 2010;170:339-343.
287. Calzavara-Pinton P, Piergiacomo C-P, Arisi M, Mariachiara A, Sereni E, Elena S, Ortel B, Bernhard O. A critical reappraisal of off-label indications for topical photodynamic therapy with aminolevulinic acid and methylaminolevulinate. Rev Recent Clin Trials. 2010;5:112-116.
288. Memon S, Hou X, Wang L, Li Y. Promotive effect of 5-aminolevulinic acid on chlorophyll, antioxidative enzymes and photosynthesis of Pakchoi (Brassica campestris ssp. chinensis var. communis Tsen et Lee). Acta Physiol Plantarum. 2009;31:51-57.
289. Korkmaz A, Korkmaz Y. Promotion by 5-aminolevulenic acid of pepper seed germination and seedling emergence under low-temperature stress. Scientia Horticulturae. 2009;119:98-102.
290. Zhang WF, Zhang F, Raziuddin R, Gong HJ, Yang ZM, Lu L, Ye QF, Zhou WJ. Effects of 5-aminolevulinic acid on oilseed rape seedling growth under herbicide toxicity stress. J Plant Growth Regul. 2008;27:159-169.
291. Korkmaz A, Korkmaz Y, Demirkiran AR. Enhancing chilling stress tolerance of pepper seedlings by exogenous application of 5-aminolevulinic acid. Environ Exp Bot. 2010;67:495-501.
292. Yiannikouris A, Jouany JP. Mycotoxins in feeds and their fate in animals: A review. Anim Res. 2002;51:81-99.
293. Kumar V, Basu MS, Rajendran TP. Mycotoxin research and mycoflora in some commercially important agricultural commodities. Crop Prot. 2008;27:891-905.
294. Reddy KRN, Abbas HK, Abel CA, Shier WT, Oliveira CAF, Raghavender CR. Mycotoxin contamination of commercially important agricultural commodities. Toxin Rev. 2009;28:154-168.
295. Sasaki K, Watanabe M, Tanaka T, Tanaka T. Biosynthesis, biotechnological production and applications of 5-aminolevulinic acid. Appl Microbiol Biotechnol. 2002;58:23-29.
296. Liu XX, Wang L, Wang YJ, Cai LL. d-Glucose enhanced 5-aminolevulinic acid production in recombinant Escherichia coli culture. Appl Biochem Biotechnol. 2010;160:822-830.
297. Irion KM, Hahn R; Karl Storz GmbH & Co. KG, assignee. Use of 5-aminolevulinic acid or a derivate thereof for photodynamic diagnosis and/or photodynamic therapy patent US 06860879. 2005.
298. Anderson RR; General Hospital Corporation, assignee. Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris patent US 06897238. 2005 May 24, 2005.
299. Kennedy JC, Pottier RH, Reid RL, Sac-Morales A, Tomalty LL; Queen's University at Kingston, assignee. Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins patent US 5955490. 1999.
300. Babilas P, Schreml S, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology: State-of-the-art. Photodermatol Photoimmunol Photomed. 2010;26:118-132.
301. Babilas P, Szeimies RM. The use of photodynamic therapy in dermatology. G Ital Dermatol Venereol. 2010;145:613-630.
302. Cappugi P, Mavilia L, Campolmi P, Reali EF, Mori M, Rossi R. New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-aminolevulinic acid. J Chemother. 2004;16:491-493.
303. De Blois AW, Grouls RJE, Ackerman EW, Wijdeven WJA. Development of a stable solution of 5-aminolaevulinic acid for intracutaneous injection in photodynamic therapy. Laser Med Sci. 2002;17:208-215.
304. Zhang L-W, Fang Y-P, Fang J-Y. Enhancement techniques for improving 5-aminolevulinic acid delivery through the skin. Dermatol Sin. 2011;29:1-7.
305. Morrow DI, McCarron PA, Woolfson AD, Juzenas P, Juzeniene A, Iani V, Moan J, Donnelly RF. Influence of penetration enhancers on topical delivery of 5-aminolevulinic acid from bioadhesive patches. J Pharm Pharmacol. 2010;62:685-695.
306. Araujo LMPD, Thomazine JA Lopez RFV. Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm. 2010;75:48-55.
307. Jia-You Fang J-Y, Wu P-C, Fang C-L, Chen C-H. Intravesical delivery of 5-aminolevulinic acid from water-in-oil nano/submicron-emulsion systems. J Pharm Sci. 2009;99:2375-2385.
308. Rose RF, Stables GI. Topical photodynamic therapy in the treatment of hidradenitis suppurativa. Photodiagnosis Photodyn Ther. 2008;5:171-175.
309. Alikhan A, Lynch PJ, Daniel B, Eisen DB. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol. 2009;60:539-561.
310. Krishnan G, Roberts MS, Grice J, Anissimov YG, Benson HA. Enhanced transdermal delivery of 5-aminolevulinic acid and a dipeptide by iontophoresis. Biopolymers. 2010;96:166-171.
311. Lopez RF, Bentley MV, Delgado-Charro MB, Salomon D, van den Bergh H, Lange N, Guy RH. Enhanced delivery of 5-aminolevulinic acid esters by iontophoresis in vitro. Photochem Photobiol. 2003;77:304-308.
312. Dixit N, Bali V, Baboota S, Alka Ahuja A, Ali J. Iontophoresis-An approach for controlled drug delivery: A review. Curr Drug Deliv. 2007;4:1-10.
313. Baxter J, Mitragotri S. Jet-induced skin puncture and its impact on needle-free jet injections: Experimental studies and a predictive model. J Control Release. 2005;106:361-373.
314. Barolet D, Boucher A. No-needle jet intradermal aminolevulinic acid photodynamic therapy for recurrent nodular basal cell carcinoma of the nose: A case report. J Skin Cancer. 2011;790509. DOI: 10.1155/2011/790509.
315. Song WC-H, Zhang R, Zheng J, Cao W. Apoptosis of SAS cells induced by sonodynamic therapy using 5-aminolevulinic acid sonosensitizer. Anticancer Res. 2011;31:39-45.
316. Ma X, Pan H, Wu G, Yang Z, Yi J. Ultrasound may be exploited for the treatment of microbial diseases. Med Hypotheses. 2009;73:18-19.
317. Arits A, van de Weert MM, Nelemans PJ, Kelleners-Smeets NWJ. Pain during topical photodynamic therapy: Uncomfortable and unpredictable. J Eur Acad Dermatol Venereol. 2010;24:1452-1457.
318. Liu BC, Farrell TJ, Patterson MS. A dynamic model for ALA-PDT of skin: Simulation of temporal and spatial distributions of ground-state oxygen, PS and singlet oxygen. Phys Med Biol. 2010;55:5913-5932.
319. Fuchs J, Weber F, Kaufmann R. Genotoxic potential of porphyrin type PSs with particular emphasis on 5-aminolevulinic acid: Implications for clinical photodynamic therapy. Free Radic Biol Med. 2000;26:537-548.
320. Kelty CJ, Brown NJ, Reed MWR, Ackroyd R. The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci. 2002;1:158-168.
321. Riddle CC, Terrell SN, Menser MB, Aires DJ, Schweiger ES. A review of photodynamic therapy (PDT) for the treatment of Acne vulgaris. J Drugs Dermatol. 2009;8:1010-1019.
322. Sakamoto FH, Lopes JD, Anderson RR. Photodynamic therapy for acne vulgaris: A critical review from basics to clinical practice: Part I. Acne vulgaris: When and why consider photodynamic therapy? J Am Acad Dermatol. 2010;63:183-193.
323. Wang X-l, Wang H-W, Zhang L-l, Guo M-X, Su L-N, Tao J-N. 5-aminolevulinic acid-mediated photodynamic diagnosis for Condylomata acuminata. Zhonghua Pifuke Zazhi. 2008;41:296-300.
324. Konopka K, Goslinski T. Prospects for photodynamic therapy in dentistry. Biophotonics Int. 2008;15:32-35.
325. Grün CH. Structure and biosynthesis of fungal α-glucans. PhD Dissertation, University of Utrecht, 2003.